Rajni Natesan
CEO, Clarified Precision Medicine
Bio: Dr. Rajni Natesan is the CEO of Clarified Precision Medicine, a company dedicated to enabling access to precision oncology at scale. She began her career as one of the first physicians on Wall Street, leading healthcare M&A and IPO deals in pharma, biotech, and med device. Rajni has led multiple companies from bench to market at the intersection of healthcare and AI/ML. A board-certified physician specialized in breast cancer, she previously served on faculty at MD Anderson Cancer Center. She completed her BA, MD, and MBA degrees from Georgetown University.
Org Info: Clarified is the only company targeting the last mile in precision oncology with a unique combination of medical group and AI-based algorithm. Clarified solves critical care gaps by translating genomic tests into therapy, providing patients and physicians with genomically-informed comprehensive treatment options, disease monitoring, and early cancer detection based on a tumor mutation panel results from any lab. As a result, patients get on the right therapy faster for improved outcomes.
What motivated you to pursue your current work?
I’ve spent my entire career helping patients with cancer, the vast majority of whom struggle with gaining access to the high quality of care we expect. This is what led me to Clarified—our team has either personally survived cancer—by having to advocate for precision therapy ourselves as patients—or spent our careers practicing oncology at the front lines of underserved communities. We understand first-hand the impact of unequal access to precision oncology, and the disparate outcomes that result. For me and my team, this is deeply personal. Precision oncology improves outcomes and lowers costs; we built Clarified to scale critical expertise for any patient, anywhere.
What distinct value does your work bring to the digital health field?
In the United States alone, there are 1.9 million new cancer cases per year, with 18 million more people living with cancer, facing either disease progression, recurrence, or less likely remission. It is widely understood that the therapeutic guidance from a molecular tumor board of experts is directly correlated with better outcomes for patients. However molecular tumor boards can only typically see the most complicated 4-8 cases per month—and usually only in an ivory tower, outside of which both resources and expertise are lacking. We’re focused on enabling access to care with our unique model of AI plus human expert.
How does your work impact your target end-users or stakeholders?
The precision oncology space is one of partnership and collaboration, where working together can multiply impact, across diverse stakeholders—from patients, to providers, to labs, to pharma. Clarified works closely with and drives value for this diverse list of stakeholders to improve patient outcomes, lower system costs, and increase appropriate utilization of NGS testing and targeted therapeutics. Clarified sits at the center of the precision medicine flywheel, impacting the critical last mile to make the flywheel turn for all stakeholders. This is a unique situation of the right tech at just the right time.
What is one exciting update or near-term opportunity that you would like to share with the digital health community?
Clarified recently closed on a $1.2M seed round, and we are already seeing a tremendous impact—in 100% of cases with Clarified guidance, oncologists report they benefit from the critical reassurance they need to make complex treatment decisions. In 30% of patient cases, Clarified’s guidance results in an oncologist changing his or her treatment decision for the patient.
Bio: Dr. Rajni Natesan is the CEO of Clarified Precision Medicine, a company dedicated to enabling access to precision oncology at scale. She began her career as one of the first physicians on Wall Street, leading healthcare M&A and IPO deals in pharma, biotech, and med device. Rajni has led multiple companies from bench to market at the intersection of healthcare and AI/ML. A board-certified physician specialized in breast cancer, she previously served on faculty at MD Anderson Cancer Center. She completed her BA, MD, and MBA degrees from Georgetown University.
Org Info: Clarified is the only company targeting the last mile in precision oncology with a unique combination of medical group and AI-based algorithm. Clarified solves critical care gaps by translating genomic tests into therapy, providing patients and physicians with genomically-informed comprehensive treatment options, disease monitoring, and early cancer detection based on a tumor mutation panel results from any lab. As a result, patients get on the right therapy faster for improved outcomes.
What motivated you to pursue your current work?
I’ve spent my entire career helping patients with cancer, the vast majority of whom struggle with gaining access to the high quality of care we expect. This is what led me to Clarified—our team has either personally survived cancer—by having to advocate for precision therapy ourselves as patients—or spent our careers practicing oncology at the front lines of underserved communities. We understand first-hand the impact of unequal access to precision oncology, and the disparate outcomes that result. For me and my team, this is deeply personal. Precision oncology improves outcomes and lowers costs; we built Clarified to scale critical expertise for any patient, anywhere.
What distinct value does your work bring to the digital health field?
In the United States alone, there are 1.9 million new cancer cases per year, with 18 million more people living with cancer, facing either disease progression, recurrence, or less likely remission. It is widely understood that the therapeutic guidance from a molecular tumor board of experts is directly correlated with better outcomes for patients. However molecular tumor boards can only typically see the most complicated 4-8 cases per month—and usually only in an ivory tower, outside of which both resources and expertise are lacking. We’re focused on enabling access to care with our unique model of AI plus human expert.
How does your work impact your target end-users or stakeholders?
The precision oncology space is one of partnership and collaboration, where working together can multiply impact, across diverse stakeholders—from patients, to providers, to labs, to pharma. Clarified works closely with and drives value for this diverse list of stakeholders to improve patient outcomes, lower system costs, and increase appropriate utilization of NGS testing and targeted therapeutics. Clarified sits at the center of the precision medicine flywheel, impacting the critical last mile to make the flywheel turn for all stakeholders. This is a unique situation of the right tech at just the right time.
What is one exciting update or near-term opportunity that you would like to share with the digital health community?
Clarified recently closed on a $1.2M seed round, and we are already seeing a tremendous impact—in 100% of cases with Clarified guidance, oncologists report they benefit from the critical reassurance they need to make complex treatment decisions. In 30% of patient cases, Clarified’s guidance results in an oncologist changing his or her treatment decision for the patient.